

---

# TRANSFORMING LIVES FOR THOSE BATTLING CANCER WITH THE SPEED & PRECISION OF AI

利用人工智能的速度和精准度改變癌症  
患者的生活

## Forward-Looking Statements / 前瞻性聲明

This presentation includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the investors who will participate in the private placement, the proposed business plan of the Company; the Company's commitment to advancing new cancer therapies; the ability of the Company to extract value from the Deep Docking AI platform; the Company's ability to execute on its business plans while maintaining high standards of research; the ability of Pharma Inventor Inc. to accurately provide medicinal chemistry support; the projected timeline and effectiveness of the Company's strategy to utilize the Deep Docking AI platform; and the Company's ability to generate shareholder value. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company.

The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition.

Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at [www.sedar.com](http://www.sedar.com).



# LEVERAGING WORLD CLASS AI TO BATTLE CANCER

## 利用世界一流的人工智能技術對抗癌症

Our mission has always been about improving the lives of those battling cancer. Now, with a robust Artificial Intelligence (AI) platform on our side, we are moving into a new era of research speed and accuracy. / 我們的使命一直是改善癌症患者的生存狀況。現在，憑借強大的人工智能（AI）平臺，我們正邁入一個研究速度和準確性的新時代。

Using advanced AI algorithms, we can quickly analyze billions of molecular structures to evaluate their potential as targeted cancer drugs. We then validate their activity using our established R&D infrastructure. This approach is innovative to developing new therapies that target DNA-damage response-related vulnerabilities that are common in many types of cancer. / 利用先進的人工智能算法，我們能夠快速分析數十億個分子結構，評估它們作為癌症靶向藥物的潛力。然後，我們會利用已建立的研發基礎設施驗證其活性。這種方法對於開發針對DNA損傷應答相關脆弱性的新療法具有創新意義，這種脆弱性在許多類型的癌症中很常見。

At Rakovina Therapeutics, we're wholly committed to pushing the boundaries of discovery and research using the latest technological advances to save lives worldwide. / 在Rakovina Therapeutics，我們全身心致力於利用最新的技術進步推動發現和研究的界限，以便在全球範圍內挽救更多生命。



10%

Increase in risk of death for every 1-month delay in cancer treatment.<sup>1</sup> / 癌症治療每延遲1個月，死亡風險就會增加<sup>1</sup>



## COMPANY SNAPSHOT / 公司簡介



Founded in 2021 to focus on the development of **new DNA-damage (DDR) response-based therapies** for the treatment of cancer

成立於2021年，專注於開發**基於DNA損傷應答（DDR）**的新型癌症治療療法



Exclusive access to **Deep Docking™ AI Platform** and **Variational AI Enki™ Platform** to rapidly screen billions of drug candidates against DNA-damage response targets

獨家使用**Deep Docking™ AI 平臺**和**Variational AI Enki™ 平臺**，針對DNA損傷應答靶點快速篩選數十億種候選藥物



Leveraging robust lead-optimization infrastructure already established in **collaboration with the University of British Columbia**

利用與卑詩大學合作建立的強大先導優化基礎設施



Experienced leadership with a track-record of success

經驗豐富的領導團隊，有成功的過往業績記錄



# TRADITIONAL DRUG DEVELOPMENT TECHNIQUES ARE COSTING LIVES


## 傳統的藥物開發技術正在讓更多患者付出生命代價

Patients can not wait long timelines over years to get the treatment they need today and tomorrow.

患者無法為了獲得今天和明天所需的治療而等待好幾年的時間。


### LONG TIMELINES / 漫長的時間線

OUTCOMES AND TIMELINES OF TRADITIONAL DRUG DEVELOPMENT / 傳統藥物開發的結果和時間線



# RAKOVINA THERAPEUTICS AI POWERED DRUG DEVELOPMENT

## Rakovina Therapeutics 基於AI的藥物開發



# TRADITIONAL DRUG DEVELOPMENT LIMITS DRUG DISCOVERY

## 傳統藥物開發限制了新藥發現


Significant obstacles challenge the advancement of life-changing innovations in new drug therapeutics.

在新藥療法方面，改變生命的創新技術的發展面臨巨大障礙。

### HIGH COSTS / 高成本

The high costs required to establish and maintain screening platforms with large libraries of compounds often hamper their use for drug discovery.<sup>1</sup> / 建立和維護擁有大量化合物庫的篩選平臺所需的高昂成本往往會阻礙其在藥物發現中的應用。<sup>1</sup>

RISING COST OF DRUG DEVELOPMENT OVER TIME  
隨著時間的推移，藥物開發成本不斷增加



### HIGH RISKS / 高風險

Drug candidate failure rate can be very high and costly due to safety or efficacy issues identified along the development lifecycle

由於在開發生命週期中發現的安全性或療效問題，候選藥物的失敗率可能非常高，而且代價高昂

### MISSED OPPORTUNITIES / 錯失的機會

The capacity to analyze drug candidates can be limited to a relatively small and sub-optimal sample size

分析候選藥物的能力可能局限於相對較小的次優樣本規模

# A NEW ERA WITH DRUG DISCOVERY THROUGH AI COLLABORATIONS

## 通過與人工智能合作研發藥物的新時代

- Exclusive access to Deep Docking™ AI platform for DNA-damage response targets / 獨家使用Deep Docking™ AI平臺研究DNA損傷應答靶點
- DDR-kinase drug discovery collaboration with Variational AI Inc. / 與Variational AI Inc.合作開展DDR-激酶藥物發現
- Rakovina Therapeutics owns rights to all novel drug candidates generated through the collaborations / Rakovina Therapeutics擁有通過合作產生的所有候選新藥的權利
- Programs overseen by Rakovina scientific advisory board member, Dr. Artem Cherkasov / 項目由Rakovina科學顧問委員會成員Artem Cherkasov博士監督

### HOW IT WORKS / 工作原理

Deep Docking and Enki are distinct computational modeling techniques to rapidly evaluate billions of compounds to identify novel therapeutic drug candidates. / Deep Docking和Enki是兩種不同的計算建模技術，用於快速評估數十億種化合物，以確定新型候選治療藥物。

There is a relationship between the biological activity of a molecule and its chemical structure. This relationship, known as structure-activity relationship (SAR), is used for predicting the biological effect of candidate drug molecules from compounds like never before using the power of the Deep Docking™ AI Platform. / 分子的生物活性與其化學結構之間存在某種關係。這種關係被稱為結構-活性關係（SAR），利用Deep Docking™ 人工智能平臺的強大功能，能夠前所未有地從化合物中預測候選藥物分子的生物效應。





# DEEP DOCKING™ AI PLATFORM: A REAL-WORLD PARADIGM SHIFT

## DEEP DOCKING™ 人工智能平臺：一場現實世界的範式轉變

Deep Docking AI Real-World Impact on COVID 19 / Deep Docking 人工智能對 COVID 19 的現實影響

# 1.3B 13億個

Drug Candidates  
Screened  
篩選的候選藥物



“The team behind Deep Docking partnered with Nvidia, Dell and UBC Advanced Research Computing (ARC) to identify potential COVID-19 therapeutics from large libraries. Even with a supercomputer, it would take years to screen 40 billion compounds with traditional methods; with Deep Docking™ we did it in 20 days. It is a paradigm shift.”<sup>1</sup>

“Deep Docking 背後的團隊與英偉達、戴爾和 UBC 高級研究計算 (ARC) 合作，從海量的化合物庫中找出潛在的 COVID-19 療法。即使使用超級計算機，用傳統方法篩選 400 億個化合物也需要數年時間；而通過使用 Deep Docking™，我們在 20 天內就完成了這項工作。這是一場範式轉變。”<sup>1</sup>

3.5 Weeks  
3.5 周

11 Months  
11 個月

**JANUARY 25**  
1月25日

COVID 19 first reported in Canada

加拿大首次報告 COVID 19

**FEBRUARY 19**  
2月19日


1,000 most promising structures published online by UBC

UBC 在線發布 1000 種最具潛力的化合物結構

**MARCH 11**  
3月11日



WHO declares global pandemic  
世界衛生組織宣布全球大流行病



**DECEMBER 22**  
12月22日

PAXLOVID granted emergency use authorization

PAXLOVID 獲得緊急使用授權

# DNA-DAMAGE RESPONSE (DDR) DNA損傷應答（DDR）

- DDRs are naturally occurring mechanisms that detect and repair DNA damage within our cells  
DDR是一種天然存在的機制，用於檢測和修復細胞內的DNA損傷。
- Many cancers harbor a defect in these natural repair mechanisms allowing mutations to accumulate and grow into life-threatening cancer  
許多癌症存在這些天然修復機制的缺陷，導致突變累積並發展成危及生命的癌症

75%

of solid tumors harbor a DDR defect<sup>1</sup> /  
實體瘤中存在DDR缺陷<sup>1</sup>


\$18B  
\$180億

DDR annual market potential by 2030<sup>2</sup> /  
到2030年，DDR每年的市場規模潛力<sup>2</sup>



# LEVERAGING AI TO REVOLUTIONIZE DRUG DEVELOPMENT

## 利用人工智能徹底改變藥物研發




### HIGH YIELD DRUG DISCOVERY

#### 高產藥物發現

Deep learning (DL) method has superior performance compared to traditional machine learning techniques. / 與傳統的機器學習技術相比，Deep Learning (DL) 方法具有卓越的性能。

Deep Docking™ yields a **6,000-fold enrichment**<sup>1</sup> in candidate drug molecules. / Deep Docking™ 使候選藥物分子**富集了6000倍**<sup>1</sup>。

Variational AI's generative AI platform Enki™ for the development of novel drug candidates **targeting key kinase enzymes** in the DNA damage response pathway. / Variational AI的生成式人工智能平臺Enki™ 用於開發**針對DNA損傷應答途徑中關鍵激酶**的新型候選藥物。



### SHORTENED TIMELINES

#### & REDUCED COST / 縮短時間，降低成本

AI algorithms screen billions of drug candidates in months versus thousands of drug candidates over years. / 與幾年篩選幾千種候選藥物相比，人工智能算法可在幾個月內篩選數十億種候選藥物。

Deep Docking™ enables up to a **100-fold acceleration**<sup>1</sup> of virtual screening compared to other AI approaches for structure-activity relationships. / 與其他人工智能方法相比，Deep Docking™可使結構-活性關係的虛擬篩選**速度提高100倍**<sup>1</sup>。

The Enki™ Generative AI can **identify DDR kinase inhibitor candidates within weeks** – far faster than traditional trial-and-error approaches that can span years. / Enki™生成式人工智能可在**幾周內確定DDR激酶抑制劑候選藥物**，遠遠快於可能需要耗費幾年的傳統試錯方法。



### MAXIMIZING SUCCESS & PIPELINE EXPANSION

#### 最大限度地提高成功率和擴大藥物研發管線

Deep Docking™ is optimized to search and evaluate for drug-like properties in the molecules it screens and to predict safety and efficacy with greater precision in its calculations and computations. / Deep Docking™經過優化，能夠在篩選的分子中搜索和評估藥物類似特性，並通過更精確的計算預測安全性和有效性。

Generative AI enhances success rates across drug development by continually refining its algorithms to increase its intelligence. This iterative intelligence enables Rakovina Therapeutics to rapidly expand our pipeline into the DDR kinase space. / 生成式人工智能通過不斷完善算法來提高智能，從而提高藥物開發的成功率。這種迭代智能使Rakovina Therapeutics能夠迅速將我們的管線擴展到DDR激酶領域。



# RAKOVINA THERAPEUTICS' DRUG DEVELOPMENT PORTFOLIO

## Rakovina Therapeutics的藥物開發組合

Multiple high-value targets already validated.

多個高價值靶點已得到驗證。

✓ PARP

✓ ATM

✓ CYC-E

✓ BRCA

✓ CHK-1

✓ ATR

✓ DNA-PK

✓ P53

DDRi Drug Development Pipeline DDRi藥物研發管線	Indication 適應症	Development Stage / 研發階段			
		Drug Discovery 藥物發現	Lead Optimization 先導化合物優化	Pre-clinical 臨床前	Clinical Trials 臨床試驗
kt-3283	PARP-resistant adult & childhood cancers				
kt-3000 series kt-3000系列 <i>Dual-function DDR inhibitors</i> 雙功能DDR抑制劑	抗PARP的成人和兒童癌症				
Deep Docking AI Platform / Deep Docking人工智能平臺		AI Discovery & Lead Optimization 人工智能發現和先導化合物優化		Confirmatory Assays 驗證試驗	Clinical Trials 臨床試驗
PARP (kt-2000AI)					
VARIATIONAL AI DDR Kinase targets / DDR激酶靶點	Solid tumors				



# COMBINING THE DEEP DOCKING™ AI PLATFORM WITH RAKOVINA CAPABILITIES FOR RAPID DDR DRUG DEVELOPMENT

## 將DEEP DOCKING™人工智能平臺與Rakovina的能力相結合，加速DDR藥物研發

COMPOUND SCREENING & LEAD OPTIMIZATION PHASE  
化合物篩選和先導化合物優化階段  
only 3-4 months from 3 years / 從3年縮短到3-4個月

COMPOUND SCREENING  
化合物篩選

5B+  
超過50億個



### ULTRA LARGE DATASETS FOR DRUG SCREENING 超大規模藥物篩選數據集

Ultra large database of more than **5 billion** drug candidate molecules is screened with Deep Docking™ for each cancer type being targeted. / 利用Deep Docking™，針對每種癌症類型在超大型數據庫中篩選超過**50億個**候選藥物分子。

Rakovina has readily available SAR data. / Rakovina擁有現成的結構-活性關係（SAR）數據。

DRUG VALIDATION LAB  
藥物驗證實驗室



### INTEGRATED PLATFORM FOR DDR DRUG VALIDATION 用於DDR藥物驗證的集成平臺

Rakovina Therapeutics's expertise and established in-house laboratory infrastructure established in partnership with UBC is used to validate compounds for advancement to human clinical trials and pharmaceutical partnerships. / Rakovina Therapeutics的專業知識以及與UBC合作建立的內部實驗室基礎設施被用於驗證化合物，以推進人體臨床試驗和制藥合作。

The level of integration between AI computations and the wet lab operation sets Rakovina apart from peers. / 人工智能計算與濕實驗室操作之間的整合程度使Rakovina在同行中脫穎而出。

QUALIFIED CLINICAL LEADS  
合格的臨床線索



### ADVANCING DDR DRUG CANDIDATES 推進DDR候選藥物

Qualified clinical leads are advanced to human trials through potential partnerships with pharma companies.

通過與制藥公司的潛在合作，合格的臨床線索將被推進到人體試驗階段。



Advancing the goal to provide cancer treatment sooner through accelerated discovery of new drug therapeutics

通過加速發現新的藥物療法，推動實現更快治療癌症的目標



## FIRST AI TARGET: A CNS PENETRANT SELECTIVE INHIBITOR OF PARP-1

### 首個人工智能靶點：選擇性抑制PARP-1的中樞神經系統穿透抑制劑

- PARP is a type of enzyme that helps repair DNA damage in cells / PARP是一種酶，幫助修復細胞中的DNA損傷
- PARP inhibitors are a type of cancer drug that work by preventing cancer cells from repairing, allowing them to die / PARP抑制劑是一種癌症藥物，通過阻止癌細胞修復，從而使其死亡
- 1st generation PARP-1/2 inhibitors have achieved commercial success in the treatment of certain breast, ovarian and prostate cancers / 第一代PARP-1/2抑制劑在治療某些乳腺癌、卵巢癌和前列腺癌方面取得了商業成功
- But they are limited by side effects and lack the ability to treat cancers that spread to the brain, giving rise to the need for a PARP-1 selective inhibitor to reduce side effects that can also treat CNS metastases / 但它們受到副作用的限制，且無法治療轉移到大腦的癌症，因此需要一種PARP-1選擇性抑制劑，以減少副作用，並能夠治療中樞神經系統中的癌細胞轉移



**\$2.3B**  
**\$23億元**

in annual revenue from first-generation PARP inhibitors<sup>1</sup> / 第一代PARP抑制劑的年收入<sup>1</sup>

# H2 2024 / H1 2025 DEEP DOCKING™ AI MILESTONES

## Deep Docking™ 人工智能 2024年下半年 / 2025年上半年的里程碑

### kt-2000AI

Best-in-class PARP-1 selective, brain penetrant cancer therapy / 一流的PARP-1選擇性、可穿透大腦的癌症治療藥物

### TIMELINE 時間線

Months (from April 2024)  
月 (自2024年4月起)

Establish Collaboration & Initiate Training of AI 建立合作關係並啟動人工智能培訓



Early fall 2024  
Receipt of initial AI Output  
2024年初秋收到人工智能初始輸出

Deep Docking of >7 billion molecules into PARP-1 target 通過Deep Docking將70億個分子與PARP-1靶點連接



Q4 2024  
PC data presentation @ Scientific Meeting / 2024年第四季度在科學會議上進行PC數據演示

Acquisition & synthesis of lead compounds 獲取和合成先導化合物



Pharma Partnering 制藥合作夥伴

Validation via in-house assays 通過內部檢測進行驗證



Pharmaceutical partnering discussions 與制藥合作夥伴討論



Deep docking on additional DDR targets 針對其他DDR靶點進行深度對接



# INVESTMENTS IN DNA-DAMAGE RESPONSE BY MULTI-NATIONAL PHARMACEUTICAL CORPORATIONS

## 跨國制藥公司在DNA損傷應答（DDR）方面的投資

### RECENT DDR TRANSACTIONS / 近几年的DDR交易

**Oct 2023 / 2023年10月**

\$1.5B (\$161M upfront)

\$15億元（預付\$1.61億）

FDA status at signing: preclinical

簽約時FDA狀態：臨床前階段



PARP-inhibitor  
PARP抑制劑



License Agreement  
許可協議



**Jun 2022 / 2022年6月**

\$1.2B (\$125M upfront)

\$12億元（預付\$1.25億）

FDA status at signing: preclinical

簽約時FDA狀態：臨床前階段



ATR-inhibitor  
ATR抑制劑



License Agreement  
許可協議



**Mar 2020 / 2020年3月**

\$1.3B (\$20M upfront)

\$13億元（預付\$2000萬）

FDA status at signing: drug discovery

簽約時FDA狀態：藥物發現



Discovery  
發現



Collaboration  
合作



**>\$25B**  
**超過\$25**  
**億**

INVESTED  
TO DATE

迄今為止的投資





# EXPERIENCED TEAM WITH A TRACK RECORD OF SUCCESS

## 經驗豐富、成績斐然的團隊

Our team has deep experience in drug discovery research, preclinical and clinical development and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. / 我們的團隊在藥物發現研究、臨床前和臨床開發以及監管事務方面擁有豐富的經驗，這些經驗對於推動突破性創新成為在腫瘤領域有可能逆天改命的治療方法是不可或缺的。



**JEFFREY BACHA, BSC, MBA / 理學學士，工商管理碩士**  
Executive Chairman/Director / 執行主席/董事

- 25 years of experience as founder and executive of multiple companies across the health sector such as Kintara Therapeutics (NASDAQ: KTRA), XBiotech, Inc. (NASDAQ: XBIT), Inimex Pharmaceuticals and Inflazyme Corp. / 25年的豐富經驗，擔任Kintara Therapeutics (NASDAQ: KTRA)、XBiotech, Inc. (NASDAQ: XBIT)、Inimex Pharmaceuticals和Inflazyme Corp. 等多家健康領域公司的創始人和高管
- Member of the National Brain Tumor Society Research Roundtable and the Board of the Leukemia Lymphoma Society of Canada / 擔任國家腦腫瘤協會研究圓桌會議和加拿大白血病淋巴瘤協會董事會成員



**MADS DAUGAARD, PHD / Mads Dugaard博士**  
President & Chief Scientific Officer / 總裁兼首席科學官

- World Leader in translational cancer research with expertise in DNA-damage response mechanisms and therapeutics targeting DNA integrity / 癌症轉化研究領域的世界領先者，具備DNA損傷應答機制和針對DNA完整性療法的專業知識
- Senior Research Scientist at Vancouver Prostate Centre, Associate Professor at University of British Columbia, Department of Urologic Sciences and Co-founder of VAR2 Pharmaceuticals (2012) and VarCT Diagnostics (2017) / 溫哥華前列腺中心高級研究科學家、卑詩大學泌尿科學系副教授、並且是VAR2 Pharmaceuticals (2012年)和VarCT Diagnostics (2017年)的聯合創始人



**DAVID HYMAN, CPA / 特許專業會計師**  
Chief Financial Officer / 首席財務官

- 20+ years of experience in financial and economic analysis for public and private enterprises in addition to financial governance and public accounting / 擁有20多年為上市和私營企業提供金融和經濟分析的經驗，以及財務管理和公共會計方面的經驗
- Previously CFO of TheraCann International, CFO and a Board Member of a TSX-V shell company (HAW Capital Corp.) that completed an RTO transaction with GOLO Mobile Inc., CFO of Merrco Payments Inc., President at Camcor Partners Ltd. / 曾擔任TheraCann International的首席財務官，多交所創業板殼公司HAW Capital Corp.的首席財務官兼董事，該公司與GOLO Mobile Inc.完成了反向收購，擔任Merrco Payments Inc.的首席財務官以及Camcor Partners Ltd.總裁



**ARTEM CHERKASOV, PHD / ARTEM CHERKASOV博士**  
SAB/Senior AI & Medicinal Chemistry Advisor  
科學顧問委員會成員/人工智能與藥物化學高級顧問

- Professor at UBC's Department of Urologic Sciences and Senior Scientist at Vancouver Prostate Centre / UBC泌尿科學系教授、溫哥華前列腺中心高級科學家
- Co-authored 200+ research papers, filed 80+ patents, and licensed 8 drug candidates to major companies as well as utilized AI-based platform, Deep Docking, to identify potential COVID-19 treatments, sharing findings with the scientific community / 合著200多篇研究論文，申請80多項專利，將8種候選藥物授權給大型醫藥公司，利用人工智能平臺Deep Docking識別潛在的COVID-19治療方案，並與科學界分享研究結果



**JOHN LANGLANDS, PHD / JOHN LANGLANDS博士**  
Chief Operating Officer / 首席運營官

- 25+ years of experience in the preclinical and clinical development of new pharmaceuticals at Naegis Pharmaceuticals, Kintara Pharmaceuticals (NASDAQ: KTRA) and Inflazyme Pharmaceuticals / 在Naegis Pharmaceuticals、Kintara Pharmaceuticals (NASDAQ: KTRA)和Inflazyme Pharmaceuticals從事新藥臨床前和臨床開發工作，擁有25年以上的經驗
- Previously Program Authority and Senior Lecturer for postgraduate training in Pharmaceutical Medicine & Drug Development UNSW in Sydney, Australia / 曾任澳大利亞悉尼新南威爾士大學藥物醫學與藥物開發研究生培訓項目負責人和高級講師

### INDEPENDENT DIRECTORS / 獨立董事

**MICHAEL LIGGETT, CPA / 特許專業會計師**  
Director / 董事

- 30 years of experience at public and private companies including Ico Therapeutics, Naegis Pharmaceuticals and Inflazyme Pharmaceuticals / 在上市和私營公司有30年的工作經驗，包括Ico Therapeutics、Naegis Pharmaceuticals和Inflazyme Pharmaceuticals
- Has completed more than \$300 million in equity and debt financings and closed more than \$200 million in acquisition transactions / 完成超過\$3億元的股權和債務融資，促成超過\$2億元的收購交易

**AL DELUCREZIA**  
Vice Chairman/ Director  
副主席/董事

- Was CEO, CFO, President and Director of Manera Capital Corp. (now GT Gold Corp.) / 曾任Manera Capital Corp. (現在的GT Gold Corp.) 首席執行官、首席財務官、總裁兼董事
- Founded Califfi Capital Corp., and has been its CEO since 2017, as well as Vincero Capital Corp, also serving as its CEO since 2019 / 創立Califfi Capital Corp.並自2017年起擔任首席執行官；創立Vincero Capital Corp.並自2019年起擔任首席執行官



# SCIENTIFIC ADVISORY BOARD / 科學顧問委員會 (SAB)



## DENNIS BROWN, PHD / DENNIS BROWN 博士

Chair, Scientific Advisory Board (SAB)/Director  
科學顧問委員會 (SAB) 主席/董事

- Involved in cancer drug discovery and development for 35+ years and currently serves as a member of the National Brain Tumor Society Research Roundtable / 在癌症藥物研發領域有超過35年的經驗，目前是國家腦腫瘤協會研究圓桌會議成員
- Founded or co-founded multiple companies including Matrix Pharmaceutical, Inc., Mountain View Pharmaceuticals, ChemGenex Pharmaceuticals and Kintara Pharmaceuticals (NASDAQ: KTRA) / 創立或聯合創立多家公司，包括Matrix Pharmaceutical, Inc.、Mountain View Pharmaceuticals、ChemGenex Pharmaceuticals和Kintara Pharmaceuticals (NASDAQ: KTRA)



## PETRA HAMERLIK, PHD / PETRA HAMERLIK 博士

SAB/Senior Drug Development Advisor / 科學顧問委員會成員/藥物開發高級顧問

- Professor, Chair of Translational Neuro-Oncology, University of Manchester, UK / 英國曼徹斯特大學轉化神經腫瘤學教授、主任
- Former director and principal scientist, AstraZeneca, DNA-damage response program / 曾擔任阿斯利康 (AstraZeneca) DNA損傷應答項目主任和首席科學家
- Highly regarded researcher, author and lecturer in neuro oncology / 神經腫瘤學領域備受推崇的研究員、作者和講師



## WANG SHEN, PHD / WANG SHEN 博士

SAB/Senior Medicinal Chemistry Advisor  
科學顧問委員會成員/高級藥物化學顧問

- Inventor of the kt-2000, kt-3000 and kt-4000 families of drug candidates under development by Rakovina Therapeutics co-author of over 40 peer-reviewed publications and co-inventor of over 40 patents / kt-2000、kt-3000和kt-4000系列候選藥物的發明者，這些候選藥物目前正在由Rakovina Therapeutics開發。共同署名發表超過40篇同行評審的論文，並共同發明超過40項專利
- 20+ years of drug discovery and project management at large pharmaceutical companies and founder of Viva Vision Biotech / 在大型製藥公司從事藥物研發和項目管理工作20多年，是Viva Vision Biotech的創始人



## ARTEM CHERKASOV, PHD / ARTEM CHERKASOV 博士

SAB/Senior AI & Medicinal Chemistry Advisor  
科學顧問委員會成員/人工智能與藥物化學高級顧問

- Professor at UBC's Department of Urologic Sciences and Senior Scientist at Vancouver Prostate Centre / UBC泌尿科學系教授、溫哥華前列腺中心高級科學家
- Co-authored 200+ research papers, filed 80+ patents, and licensed 8 drug candidates to major companies as well as utilized AI-based platform, Deep Docking, to identify potential COVID-19 treatments, sharing findings with the scientific community / 合著200多篇研究論文，申請80多項專利，將8種候選藥物授權給大型醫藥公司，利用人工智能平臺Deep Docking 識別潛在的COVID-19治療方案，並與科學界分享研究結果



## LEONARD POST, PHD / LEONARD POST 博士

SAB/Senior Drug Development Advisor / 科學顧問委員會成員/藥物開發高級顧問

- 35+ years of drug development and leadership experience in the pharmaceutical and biotechnology industry spanning companies of all sizes / 在製藥和生物技術行業擁有超過35年的藥物開發和領導經驗，涉及各類規模的公司
- Previously chief scientific officer of BioMarin, senior vice president of research and development for Onyx Pharmaceuticals and vice president of discovery research for Parke-Davis Pharmaceuticals / 曾擔任BioMarin的首席科學官、Onyx Pharmaceuticals的研發高級副總裁以及Parke-Davis Pharmaceuticals的發現研究副總裁



## NEIL SANKAR, MD / 醫學博士

SAB/Executive Medical Director / 科學顧問委員會成員/執行醫療總監

- Held Clinical development positions within leading Biotech/Pharma including Genentech, Medimmune, Pharmacyclis, Fiveprime, Otsuka, Portola, CBT Pharmaceuticals, LSK biopharma and Rhizen Pharmaceuticals / 曾在多家領先的生物技術/製藥公司擔任臨床開發職位，包括Genentech、Medimmune、Pharmacyclis、Fiveprime、Otsuka、Portola、CBT Pharmaceuticals、LSK Biopharma和Rhizen Pharmaceuticals
- Extensive experience in the application of US Food and Drug Administration regulations / 在美國食品藥品管理局 (FDA) 法規應用方面擁有大量經驗




# MARKET SUMMARY

## 資本市場概述

EXCHANGE / 交易所	<b>TSX Venture Exchange (TSXV)</b> 多倫多證券交易所創業板
SYMBOL / 交易代碼	<b>RKV</b>
SECTOR / INDUSTRY 部門/行業	<b>Biopharmaceuticals / Oncology</b> 生物制藥/腫瘤
26 WEEK RANGE <sup>1</sup> 過去26周股價波動範圍 <sup>1</sup>	<b>CAD \$0.07 -0.14</b> <b>\$0.07 -0.14加元</b>
SHARES OUTSTANDING 流通股數量	<b>90,289,175</b>
FULLY DILUTED 完全稀釋後	<b>128,184,676</b>
WARRANTS <sup>2</sup> / 認股權證 <sup>2</sup>	<b>22,990,000</b>
MARKET CAPITALIZATION <sup>1</sup> 市值 <sup>1</sup>	<b>CAD ~ \$8.13 million</b> <b>\$813萬加元</b>
AUDITORS / 審計事務所	<b>Davidson &amp; Company LLP</b>

### OWNERSHIP SUMMARY

#### 持股情況概述



1) Prices are as of September 5, 2024 / 截止2024年9月5日的價格

2) \$0.19 weighted average exercise price and 2.7 years weighted average remaining life as of July 31, 2024 – consists of 3,028,000 warrants issued with convertible debt (\$0.15, 1.4 years remaining life), 19,950,000 2024 Private Placement warrants (\$0.20, 3.0 years remaining life), and 12,000 finders warrants (\$0.20, 3.0 years remaining life). / 截至2024年7月31日, 加權平均行使價為\$0.19, 加權平均剩餘有效期為2.7年 - 包括3,028,000份與可轉換債務一起發行的認股權證(行使價格\$0.15, 剩餘有效期為1.4年)、19,950,000份2024年私募認股權證(行使價格\$0.20, 剩餘有效期為3.0年)和12,000份中間人認股權證(行使價格\$0.20, 剩餘有效期為3.0年)。

Source / 來源: FactSet

# WHY INVEST IN RAKOVINA THERAPEUTICS

## 為什麼要投資Rakovina Therapeutics?

A paradigm shift in drug discovery and therapeutic intervention to treat cancer.

一場癌症藥物發現和治療幹預的範式轉變。



**\$18B ADDRESSABLE MARKET**

**\$180億的可尋址市場**

Broad cancer application targeting the **75% of all solid tumors** that harbor a DNA-Damage response defect.

在癌症領域應用廣泛，針對**75%**存在DNA損傷應答缺陷的**實體腫瘤**。



**LEVERAGING SUPERIOR AI PLATFORMS TO ACCELERATE DEVELOPMENT**

利用卓越的人工智能平臺加快研發速度

Deep Docking enables up to a **100-fold acceleration**<sup>3</sup> of virtual screening and a **6,000-fold enrichment**<sup>3</sup> in candidate drug molecules with greater precision for maximizing success.

Deep Docking使虛擬篩選的速度**提高了100倍**<sup>3</sup>，候選藥物分子的**富集提高了6000倍**<sup>3</sup>，而且更加精確，從而最大限度地提高了成功率。



**REAL-WORLD PROVEN AI TECHNOLOGIES**

在現實世界中经过验证的人工智能技术

**Deep Docking put to the test during COVID-19.** Successful screening of billions of compounds in just 20 days<sup>4</sup> and drug approval in 11 months. / **在COVID-19期間對Deep Docking進行測試**，在短短20天內成功篩選了數十億個化合物，最終在11個月內獲得藥物批准。

Variational AI platform validated through **partnerships with major pharma** / **通過與大型製藥公司合作**，驗證了Variational人工智能平臺



**UNMATCHED INTEGRATED DRUG VALIDATION**

無與倫比的綜合藥物驗證

A fully integrated DDR drug validation platform to optimize artificial intelligence outputs with **in-house laboratory infrastructure and wet lab operations** to advance human clinical trials and pharmaceutical partnerships.

完全集成的DDR藥物驗證平臺，可優化人工智能輸出與**內部實驗室基礎設施和濕實驗室操作**，以推進人體臨床試驗和製藥合作。



**BRING-TO-MARKET MANAGEMENT TEAM**  
推向市場的管理團隊


Deep **experience in drug discovery** research, development, and the approval process to advance breakthrough innovation.

在**藥物發現**研究、研發和審批流程以推動突破性創新方面擁有大量的**經驗**。

**IN THE MEDIA**  
媒體報道



**TOP 10**

**THE  
GLOBE  
AND  
MAIL** 

**UNDERVALUED  
BIOTECHNOLOGY INDUSTRY STOCKS**

By the Globe & Mail



**READ ARTICLE**  
掃碼閱讀



---

**OVER 70% OF PHARMACEUTICAL  
BREAKTHROUGHS STEM FROM THE  
EFFORTS OF SMALL BIOTECH COMPANIES  
LIKE RAKOVINA THERAPEUTICS**

**超過70%的藥物突破源自於像Rakovina  
Therapeutics這樣的小型生物技術公司的不  
懈努力**



[info@rakovinatherapeutics.com](mailto:info@rakovinatherapeutics.com)  
[rakovinatherapeutics.com](http://rakovinatherapeutics.com)

105 – 1008 Beach Avenue  
Vancouver, British Columbia  
Canada V6E 1T7